Triptonide Inhibits the Cervical Cancer Cell Growth Via Downregulating the RTKs and Inactivating the Akt-mTOR Pathway

Overview

Journal Oxid Med Cell Longev

Publisher Wiley

Specialties Cell Biology
Endocrinology

Date 2024 Sep 16

PMID 39282148

Authors

Li-Na Zhou

Shi-Qing Peng

Xue-Lian Chen

Xiao-Ren Zhu

An-Qi Jin

Yuan-Yuan Liu

Li-Xia Zhu

Ya-Qun Zhu

Affiliations

Soon will be listed here.

Abstract

The high incidence and mortality of cervical cancer (CC) require an urgent need for exploring novel valuable therapeutics. Triptonide (TN) is a small molecule monomer extracted from the Chinese herb . Our results showed that TN, at only nanomolar concentrations, strongly inhibited growth, colony formation, proliferation, migration, and invasion of established and primary human cervical cancer cells. TN induced apoptosis and cell cycle arrest in cervical cancer cells. Moreover, cervical cancer cell migration and invasion were suppressed by TN. It was however noncytotoxic and proapoptotic to normal cervical epithelial cells and human skin fibroblast cells. Gene set enrichment analysis (GSEA) of RNA sequencing data of differentially expressed genes (DEGs) in TN-treated cervical cancer cells implied that DEGs were enriched in the receptor tyrosine kinase (RTK) signaling and PI3K-Akt-mTOR cascade. In cervical cancer cells, RTKs, including EGFR and PDGFR, were significantly downregulated and Akt-mTOR activation was largely inhibited after TN treatment. , oral administration of TN significantly inhibited subcutaneous cervical cancer xenograft growth in nude mice. EGFR and PDGFR downregulation as well as Akt-mTOR inactivation was detected in TN-treated HeLa xenograft tumor tissues. Thus, TN inhibits human cervical cancer cell growth and . Its anticervical cancer activity was associated with RTK downregulation and Akt-mTOR inactivation.

Citing Articles

Triptolide induces immunogenic cell death in cervical cancer cells via ER stress and redox modulation.

Zheng Z, Chen Y, Wang C, Li L, Tan B Am J Cancer Res. 2025; 15(1):69-83.

PMID: 39949945 PMC: 11815369. DOI: 10.62347/XNVR3799.

References

Sun Y, Xiao L, Wang D, Ji Y, Yang Y, Ma R . Triptolide inhibits viability and induces apoptosis in liver cancer cells through activation of the tumor suppressor gene p53. Int J Oncol. 2017; 50(3):847-852. DOI: 10.3892/ijo.2017.3850. View

Yang F, Ren L, Zhuo L, Ananda S, Liu L . Involvement of oxidative stress in the mechanism of triptolide-induced acute nephrotoxicity in rats. Exp Toxicol Pathol. 2011; 64(7-8):905-11. DOI: 10.1016/j.etp.2011.03.013. View

Caicedo-Granados E, Lin R, Fujisawa C, Yueh B, Sangwan V, Saluja A . Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma. Oral Oncol. 2014; 50(12):1149-56. PMC: 4678773. DOI: 10.1016/j.oraloncology.2014.09.013. View

Zhang L, Wu J, Ling M, Zhao L, Zhao K . The role of the PI3K/Akt/mTOR signalling pathway in human cancers induced by infection with human papillomaviruses. Mol Cancer. 2015; 14:87. PMC: 4498560. DOI: 10.1186/s12943-015-0361-x. View

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Liu L, Wang Y, Geng C, Wang A, Han S, You X . CD155 Promotes the Progression of Cervical Cancer Cells Through AKT/mTOR and NF-κB Pathways. Front Oncol. 2021; 11:655302. PMC: 8216081. DOI: 10.3389/fonc.2021.655302. View

Yao J, Zhang L, Zhao X, Ling Hu , Jiang Z . Simultaneous determination of triptolide, wilforlide A and triptonide in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry. Biol Pharm Bull. 2006; 29(7):1483-6. DOI: 10.1248/bpb.29.1483. View

Wong K, Chan J, Chan K, Tam P, Yang D, Fan S . Immunochemical characterization of the functional constituents of Tripterygium wilfordii contributing to its anti-inflammatory property. Clin Exp Pharmacol Physiol. 2007; 35(1):55-9. DOI: 10.1111/j.1440-1681.2007.04740.x. View

Ramakrishnan V, de Haydu C, Wilkinson P, Hooda U, Giri B, Oleas J . Minnelide, a prodrug, inhibits cervical cancer growth by blocking HPV-induced changes in p53 and pRb. Am J Cancer Res. 2021; 11(5):2202-2214. PMC: 8167699. View

10.

Bivona T, Doebele R . A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nat Med. 2016; 22(5):472-8. PMC: 5384713. DOI: 10.1038/nm.4091. View

11.

Bloom J, Cross F . Multiple levels of cyclin specificity in cell-cycle control. Nat Rev Mol Cell Biol. 2007; 8(2):149-60. DOI: 10.1038/nrm2105. View

12.

de Azevedo C, Thuler L, de Mello M, Ferreira C . Neoadjuvant Chemotherapy Followed by Chemoradiation in Cervical Carcinoma: A Review. Int J Gynecol Cancer. 2016; 26(4):729-36. DOI: 10.1097/IGC.0000000000000663. View

13.

Noel P, Von Hoff D, Saluja A, Velagapudi M, Borazanci E, Han H . Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol Sci. 2019; 40(5):327-341. DOI: 10.1016/j.tips.2019.03.002. View

14.

Dong F, Yang P, Wang R, Sun W, Zhang Y, Wang A . Triptonide acts as a novel antiprostate cancer agent mainly through inhibition of mTOR signaling pathway. Prostate. 2019; 79(11):1284-1293. DOI: 10.1002/pros.23834. View

15.

Olusola P, Banerjee H, Philley J, Dasgupta S . Human Papilloma Virus-Associated Cervical Cancer and Health Disparities. Cells. 2019; 8(6). PMC: 6628030. DOI: 10.3390/cells8060622. View

16.

Polivka Jr J, Janku F . Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2013; 142(2):164-75. DOI: 10.1016/j.pharmthera.2013.12.004. View

17.

Singh V, Ram M, Kumar R, Prasad R, Roy B, Singh K . Phosphorylation: Implications in Cancer. Protein J. 2017; 36(1):1-6. DOI: 10.1007/s10930-017-9696-z. View

18.

Zhu X, Peng S, Wang L, Chen X, Feng C, Liu Y . Identification of phosphoenolpyruvate carboxykinase 1 as a potential therapeutic target for pancreatic cancer. Cell Death Dis. 2021; 12(10):918. PMC: 8497628. DOI: 10.1038/s41419-021-04201-w. View

19.

Kontostathi G, Zoidakis J, Anagnou N, Pappa K, Vlahou A, Makridakis M . Proteomics approaches in cervical cancer: focus on the discovery of biomarkers for diagnosis and drug treatment monitoring. Expert Rev Proteomics. 2016; 13(8):731-45. DOI: 10.1080/14789450.2016.1210514. View

20.

Zhang M, Tan S, Yu D, Zhao Z, Zhang B, Zhang P . Triptonide inhibits lung cancer cell tumorigenicity by selectively attenuating the Shh-Gli1 signaling pathway. Toxicol Appl Pharmacol. 2019; 365:1-8. DOI: 10.1016/j.taap.2019.01.002. View